We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Engineered Ligand Protein Protects Mice from Developing Cancer

By LabMedica International staff writers
Posted on 04 Mar 2019
A team of cancer researchers has developed a recombinant protein molecule that, when injected into mice, was able to protect the animals against subsequent tumor challenge irrespective of the tumor type.

Investigators at the University of Louisville (Kentucky, USA) were working with SA-4-1BBL, an engineered oligomeric form of the 4-1BBL ligand protein. More...
4-1BB ligand is a membrane bound member of the TNF (tumor necrosis factor) superfamily that is expressed on activated B-lymphocytes, macrophages, and dendritic cells. The ligand is specific for the 4-1BB (CD137) receptor and may play a role in inducing the proliferation of activated peripheral blood T-lymphocytes. 4-1BB is a type two transmembrane glycoprotein receptor belonging to the TNF superfamily, expressed on activated T lymphocytes. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule.

T-cells require two signals to become fully activated. A first signal, which is antigen-specific, is provided through the T-cell receptor (TCR), which interacts with peptide-MHC molecules on the membrane of antigen presenting cells (APC). A second signal, the co-stimulatory signal, is antigen nonspecific and is provided by the interaction between co-stimulatory molecules expressed on the membrane of APC and the T-cell.

Previous studies have shown that co-stimulation through the 4-1BB receptor generates robust CD8+ T-effector and memory responses. The only known ligand, 4-1BBL, is a trimeric transmembrane protein that has no co-stimulatory activity as a soluble molecule. Thus, agonistic antibodies to the receptor have been used for cancer immunotherapy in preclinical models and are currently being evaluated in the clinic.

The investigators reported in the February 15, 2019, issue of the journal Cancer Research that treatment with SA-4-1BBL as a single agent was able to protect mice against subsequent tumor challenge irrespective of the tumor type. Protection was longlasting (more than eight weeks) and a bona fide property of SA-4-1BBL, as treatment with an agonistic antibody to the 4-1BB receptor was ineffective in generating immune protection against tumor challenge.

Mechanistically, SA-4-1BBL significantly expanded IFNgamma-expressing, preexisting memory-like CD44+CD4+ T-cells and NK cells in naïve mice as compared with the agonistic antibody. In vivo blockade of IFNgamma or depletion of CD4+ T or NK cells, but not CD8+ T or B-cells, abrogated the immunopreventive effects of SA-4-1BBL against cancer.

“The novelty we are reporting is the ability of this molecule to generate an immune response that patrols the body for the presence of rare tumor cells and to eliminate cancer before it takes hold in the body,” said senior author Dr. Haval Shirwan, professor of microbiology and immunology at the University of Louisville. “Generally, the immune system will need to be exposed to the tumor, recognize the tumor as dangerous, and then generate an adaptive and tumor-specific response to eliminate the tumor that it recognizes. Thus, our new finding is very surprising because the immune system has not seen a tumor, so the response is not to the presence of a tumor. With advances in cancer screening technologies and genetic tools to identify high-risk individuals, we ultimately are hoping to have the opportunity to test the SA-4-1BBL molecule for immunoprevention in individuals who are predisposed to certain cancers, as well as in the presence of precancerous lesions.”

Related Links:
University of Louisville


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.